Indications & Dose:
Benign gastric ulceration
Duodenal ulceration
Child 1–5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day)
Child 6 months–2 years: 2–4 mg/kg twice daily
Child 3–11 years: 2–4 mg/kg twice daily (max. per dose150 mg)
Child 12–17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night
Adult: 150 mg twice daily for 4–8 weeks, alternatively300 mg once daily for 4–8 weeks, dose to be taken at night
Chronic episodic dyspepsia
Adult: 150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night
NSAID-associated gastric ulceration
Adult: 150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night
NSAID-associated duodenal ulcer
Adult: 300 mg twice daily for 4 weeks, to achieve ahigher healing rate
Prophylaxis of NSAID-associated gastric ulcer
Prophylaxis of NSAID-associated duodenal ulcer
Adult: 300 mg twice daily
Gastro-oesophageal reflux disease
Adult: 150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night
Moderate to severe gastro-oesophageal reflux disease
Adult: 600 mg daily in 2–4 divided doses for up to 12 weeks
Long-term treatment of healed gastro-oesophageal reflux disease
Adult: 150 mg twice daily
Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics
Adult: 150 mg, dose to be given at onset of labour, then 150 mg every 6 hours
Gastric acid reduction (prophylaxis of acid aspiration)
in surgical procedures
Adult: 50 mg, to be given 45–60 minutes before induction of anaesthesia, intravenous injection diluted to 20mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening
Prophylaxis of stress ulceration
Adult: 50 mg every 8 hours, dose to be diluted to 20mLand given over at least 2 minutes, then (by mouth)150 mg twice daily, may be given when oral feeding commences
Reflux oesophagitis and other conditions where gastric acid reduction is beneficial
Child 1–5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day)
Child 6 months–2 years: 2–4 mg/kg twice daily
Child 3–11 years: 2–4 mg/kg twice daily (max. per dose150 mg); increased to up to 5 mg/kg twice daily (max.per dose 300 mg), dose increase for severe gastrooesophageal disease
Child 12–17 years: 150 mg twice daily, alternatively300 mg once daily, dose to be taken at night, thenincreased if necessary to 300 mg twice daily for up to12 weeks in moderate to severe gastro-oesophagealreflux disease, alternatively increased if necessary to150 mg 4 times a day for up to 12 weeks in moderate tosevere gastro-oesophageal reflux disease
Conditions where reduction of gastric acidity is beneficial and oral route not available
Adult: 50 mg every 6–8 hours
Adult: 50 mg, dose to be diluted to 20mL and givenover at least 2 minutes; may be repeated every6–8 hours
ADMINSTRATION: For slow intravenous injection dilute to a concentration of 2.5mg/ml with Glucose 5% or Sodium Chloride 0.9%, give over at least 3 minutes.
Contraindications:
Hypersensitivity.
Cautions:
Precautions:
Renal and hepatic function impairment, elderly, gastric malignancy, rapid IV administration, immunocompromised patients.
Pregnancy: Safety not established.
Breast-feeding: Use with caution.
Old age: May be used.
Interaction:
Drugs
Cefuroxine; cefpodoxime; enoxacin; ketaconazole: Reduction in gastric acidity reduces absorption, decreased plasma levels, potential for therapeutic failure
Glipizide; glyburide; tolbutamide: Increased absorption of these drugs, potential for hypoglycemia
Nifedipine, nitrendipine, nisoldipine: Increased concentrations of these drugs
Warnings:
Adverse Effects:
Lactations:
Special Precautions:
Counselling:
Side Effects Or Adverse Reactions:
Patient And Carer Advice:
© Pakistan Drug Directory. All Rights Reserved.
Designed By: Pakistan Drug Directory Team